Natera CEO: We’re using DNA tech to change disease management

Jim Cramer chats with Natera CEO Steve Chapman about how the company is growing its reproductive health system and proprietary technology to alter how disease is managed worldwide.

Chapman said Natera is changing the way disease is detected using small amounts of DNA. He said the first application of the technology was prenatal testing, which is now a $300 million business. The company is now expanding their research to include oncology and organ rejection.

There are currently one million tests a year for colorectal cancer that Natera could tap into, Chapman explained. While 150,000 patients have symptoms of the disease, another one million patients are in remission. Natera is working to detect the recurrence of cancer up to eight months before it can be detected via traditional imaging. Early detection of recurring cancer would save lives, he added.

As for organ transplants, Chapman said there are 200,000 patients living with kidney transplants, but up to half of them will reject their organ in the first 10 years. Natera is again studying early detection of these events to help save lives.

For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://www.cnbc.com/pro/?__source=yo...

» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic

Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC

#CNBC
#CNBC TV